Metaptys
0554.664.311 · rovalta.com · 20/09/2026
ACTIVE
Metaptys
Financial year 2025 · closed on 31/12/2025
Net result
218,0 k €
+20.5% YoY
Gross margin
1,3 M €
+4.2% YoY
Equity
1,3 M €
+20.0% YoY
Workforce
7,3 ETP
-11.0% YoY
Overview
What does Metaptys do?
Metaptys is a Public limited company incorporated in 2014. Its main activity is: Other professional, scientific and technical activities n.e.c.. Its registered office is in Leuven. It employs on average 7,3 ETP workers (FTE).
Legal situation
● Normal situation
BCE/KBO no. / VAT
BE 0554.664.311
Incorporation
04/06/2014
Legal form
Public limited company
Registered office
Gaston Geenslaan 3
3001 Leuven · FlandreSee on map
3001 Leuven · FlandreSee on map
Contributed capital
232 053,00 €
Latest accounts
31/12/2025
Average workforce
7,3 ETP
Activities (NACE)
74909Other professional, scientific and technical activities n.e.c.· main74999Other professional, scientific and technical activities n.e.c.71209Technical testing and analysis71209Technical testing and analysis72101Research and experimental development on natural sciences and engineering72109Research and experimental development on natural sciences and engineering+2
Joint committees (2)
- 116
- 207
Contacts
1 public detail availableLog in to view
Signals
ProfitableSolid equityLow riskGood liquidityPositive cashflowPositive EBITDAHealthy social debts
Available with a Rovalta subscriptionTry for 7 days
Financials
Trend over 11 financial years
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||||||||||||||
| Gross margin | 1,3 M € | +4.2% | 1,2 M € | -46.7% | 2,3 M € | +2854% | -84,7 k € | -211% | -27,2 k € | -875% | -2,8 k € | +57.2% | -6,5 k € | -45.5% | -4,5 k € | +99.0% | -434,6 k € | +60.0% | -1,1 M € | +52.9% | -2,3 M € |
| EBITDA | 382,8 k € | +4.5% | 366,2 k € | -67.6% | 1,1 M € | +517% | -270,8 k € | -860% | -28,2 k € | -641% | -3,8 k € | +48.4% | -7,4 k € | -30.8% | -5,6 k € | +98.7% | -435,5 k € | +60.0% | -1,1 M € | +53.1% | -2,3 M € |
| Operating result | 224,5 k € | +17.9% | 190,4 k € | -80.3% | 966,2 k € | +424% | -298,3 k € | -958% | -28,2 k € | -641% | -3,8 k € | +48.4% | -7,4 k € | -30.8% | -5,6 k € | +98.7% | -435,7 k € | +60.0% | -1,1 M € | +53.1% | -2,3 M € |
| Net result | 218,0 k € | +20.5% | 180,9 k € | -81.0% | 950,6 k € | +411% | -305,9 k € | -105% | 6,6 M € | +13.2% | 5,8 M € | +438% | -1,7 M € | -427% | 529,4 k € | +218% | -449,6 k € | +55.1% | -1,0 M € | +57.6% | -2,4 M € |
| Balance sheet | |||||||||||||||||||||
| Equity | 1,3 M € | +20.0% | 1,1 M € | +19.9% | 907,2 k € | +2187% | -43,5 k € | -117% | 262,5 k € | -97.0% | 8,8 M € | -29.3% | 12,4 M € | -12.2% | 14,2 M € | -57.4% | 33,2 M € | -4.2% | 34,7 M € | -2.8% | 35,7 M € |
| Total assets | 1,6 M € | +6.7% | 1,5 M € | -4.7% | 1,6 M € | +57.1% | 1,0 M € | +282% | 267,6 k € | -97.0% | 8,8 M € | -29.3% | 12,4 M € | -12.2% | 14,2 M € | -57.4% | 33,3 M € | -5.3% | 35,1 M € | -2.7% | 36,1 M € |
| Cash | 1,2 M € | +10.1% | 1,1 M € | +38.8% | 760,3 k € | +160% | 292,9 k € | +17.5% | 249,3 k € | -10.9% | 279,8 k € | -93.6% | 4,4 M € | +199% | 1,5 M € | -89.3% | 13,7 M € | -52.7% | 29,1 M € | -11.7% | 32,9 M € |
| Debts | 329,0 k € | -20.0% | 411,4 k € | -41.2% | 700,0 k € | -34.3% | 1,1 M € | +20545% | 5,2 k € | +340% | 1,2 k € | -66.0% | 3,5 k € | +70.7% | 2,0 k € | -94.9% | 39,4 k € | -91.0% | 437,1 k € | +7.0% | 408,4 k € |
| Other | |||||||||||||||||||||
| Workforce | 7,3 ETP | -11.0% | 8,2 ETP | -27.4% | 11,3 ETP | +54.8% | 7,3 ETP | – | – | – | – | – | – | 0,1 ETP | |||||||
Estimate
Indicative valuation
As an indication, this company is worth
between 2,5 M€ and 5 M€
See the valuationGovernance
Board of directors
Seen on filing of 31/12/2025 · 3 active · 13 ended
Active mandates
Ended mandates
At this address
Other companies at this address
| Company | CBE no. |
|---|---|
AstriVax Therapeutics● Active | 0787.990.881 |
AUGUSTINE THERAPEUTICS● Active | 0722.705.230 |
COULTREON BIOPHARMA● Active | 1019.429.814 |
K5 Therapeutics● Active | 0757.718.072 |
Montis Biosciences● Active | 0730.979.429 |
Perseus Biomics● Active | 0650.946.412 |
QUOMAK● Active | 0448.488.111 |
ReWind Therapeutics● Active | 0682.626.216 |
| 1040.853.946 | |
Tavira Therapeutics● Active | 0802.591.262 |
VEDRA THERAPEUTICS● Active | 1039.565.628 |
Financials
Annual accounts
Full financial information
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|---|
| Type of account | Abridged model | Abridged model | Abridged model | Abridged model | Abridged model | Abridged model |
| Start of the financial year | 01/01/2025 | 01/01/2024 | 01/01/2023 | 01/01/2022 | 01/01/2021 | 01/01/2020 |
| Closing of the financial year | 31/12/2025 | 31/12/2024 | 31/12/2023 | 31/12/2022 | 31/12/2021 | 31/12/2020 |
| Length of the financial year | 12 months | 12 months | 12 months | 12 months | 12 months | 12 months |
| Filing date | 22/05/2026 | 24/07/2025 | 30/08/2024 | 22/08/2023 | 26/07/2022 | 19/08/2021 |
| General meeting | 15/05/2026 | 30/06/2025 | 29/07/2024 | 07/08/2023 | 19/07/2022 | 30/06/2021 |
| Currency of the financial year | EUR | EUR | EUR | EUR | EUR | EUR |
| NBB quality label | Satisfying controls | Satisfying controls | Satisfying controls | Satisfying controls | Satisfying controls | Satisfying controls |
Ratios
Financial ratios
Looking for more information about this company?
Try for 7 daysFilings
Annual accounts filings
11 filings with the NBB
| Model | Closing | General meeting | Filed | Language | Document |
|---|---|---|---|---|---|
| Abridged model | 31/12/2025 | 15/05/2026 | 22/05/2026 | Dutch | |
| Abridged model | 31/12/2024 | 30/06/2025 | 24/07/2025 | Dutch | |
| Abridged model | 31/12/2023 | 29/07/2024 | 30/08/2024 | Dutch | |
| Abridged model | 31/12/2022 | 07/08/2023 | 22/08/2023 | Dutch | |
| Abridged model | 31/12/2021 | 19/07/2022 | 26/07/2022 | Dutch | |
| Abridged model | 31/12/2020 | 30/06/2021 | 19/08/2021 | Dutch | |
| Abridged model | 31/12/2019 | 15/05/2020 | 17/06/2020 | Dutch | |
| Abridged model | 31/12/2018 | 28/06/2019 | 21/08/2019 | Dutch | |
| Abridged model | 31/12/2017 | 15/05/2018 | 27/09/2018 | Dutch | |
| Abridged model | 31/12/2016 | 30/06/2017 | 31/08/2017 | Dutch | |
| Abridged model | 31/12/2015 | 17/05/2016 | 23/06/2016 | Dutch |
Valuation
Estimate
Indicative valuation
Order of magnitude
As an indication, this company is worth
between 2,5 M€ and 5 M€
The detail comes with the Business plan: low and high bounds, the valuation bridge for each financial year, transaction multiples by sector and size, group valuation and exports.
Disclaimer
Indicative estimate based on public sector multiples and the filed annual accounts. It is neither a certified valuation nor financial or investment advice.
Directors & structure
Governance
Board of directors
Seen on filing of 31/12/2025 · 3 active · 13 ended
Active mandates
Ended mandates
Shareholders
Ownership and network
Looking for more information about this company?
Try for 7 daysPublications
Belgian Official Gazette
Belgian Official Gazette publications
- Mandates06/05/2026ONTSLAGEN - BENOEMINGEN
- Mandates29/12/2023ONTSLAGEN - BENOEMINGEN
- Registered office16/11/2022MAATSCHAPPELIJKE ZETEL
- Other04/08/2022DIVERSEN
- Registered office05/05/2022MAATSCHAPPELIJKE ZETEL
- Mandates25/02/2022ONTSLAGEN - BENOEMINGEN
- Mandates03/11/2021STATUTEN (VERTALING, COÖRDINATIE, OVERIGE WIJZIGINGEN, ) - KAPITAAL - AANDELEN - ONTSLAGEN - BENOEMINGEN
- Mandates27/10/2021ONTSLAGEN - BENOEMINGEN
Source: Belgian Official Gazette
Similar companies
Competition
Similar companies
A company's peers, by sector and size, are included in the Business plan.
See the Business planTimeline
Timeline
- 2025Annual accounts 2025218,0 k €↑
- 2024Annual accounts 2024180,9 k €↓
- 2023Annual accounts 2023950,6 k €↑
- 2022Annual accounts 2022-305,9 k €↓
- 2021Annual accounts 20216,6 M €↑
- 2020Annual accounts 20205,8 M €↑
- 2019Annual accounts 2019-1,7 M €↓
- 2018Annual accounts 2018529,4 k €↑
- 2017Annual accounts 2017-449,6 k €↑
- 2016Annual accounts 2016-1,0 M €↑
- 2015Annual accounts 2015-2,4 M €
- 04/06/2014IncorporationPublic limited company